Nvidia Expands Robotics and Life Sciences AI Platforms as Physical AI Strategy Accelerates

Key Takeaways

• Nvidia launched the BioNeMo Agent Toolkit to support AI-driven research in life sciences.

• The company also unveiled Halos for Robotics, a safety platform for robotics and physical AI.

• More than 50 organizations have adopted the BioNeMo Agent Toolkit, including OpenAI, Anthropic, Lilly and Natera.

• Agility Robotics is the first company to integrate Nvidia Halos into its robotics safety architecture.

What Happened

Nvidia Corp. (NASDAQ: NVDA) announced two new artificial intelligence platforms aimed at expanding its presence in robotics and scientific research.

The company introduced the NVIDIA BioNeMo Agent Toolkit, a platform that enables AI agents to perform specialized life sciences tasks, including protein structure prediction, molecular docking, genomic analysis, biomarker discovery and generative chemistry.

Separately, Nvidia launched NVIDIA Halos for Robotics, which it describes as a full-stack safety platform designed for robotics and physical AI applications. The system combines AI computing hardware, safety software, sensor technologies and certification capabilities to support the deployment of autonomous machines.

Why It Matters

The announcements reflect Nvidia's strategy to broaden the use of its AI technologies beyond semiconductor hardware by providing software platforms and development tools for enterprise customers.

As industries increasingly adopt AI-powered robotics and automation, demand for integrated computing, software and safety solutions is expected to grow. Nvidia's expanding ecosystem also strengthens customer reliance on its AI infrastructure across healthcare, manufacturing and industrial automation.

Key Details

According to Nvidia, the BioNeMo Agent Toolkit builds on more than a decade of life sciences software development and integrates technologies including NIM microservices, Parabricks, NeMo and Nemotron.

The company said more than 50 organizations are already using the platform, including OpenAI, Anthropic, Eli Lilly, and Natera. Nvidia also said collaborations extend to laboratory automation providers, AI-focused biotechnology companies and scientific data platform developers.

Nvidia stated that the toolkit can significantly reduce virtual screening times for drug discovery workflows and has demonstrated up to twice the performance for RosettaFold3 protein design models through work with the University of Washington's Institute for Protein Design.

The newly introduced Halos for Robotics platform incorporates safety software, computing systems, sensor integration and an ANAB-accredited inspection laboratory intended to support functional safety certification.

Agility Robotics, whose Digit humanoid robot is deployed in facilities operated by Amazon, GXO, Schaeffler and Toyota Motor Manufacturing Canada, is the first company to integrate Halos into its robotics safety framework.

Market Impact

The latest product launches reinforce Nvidia's efforts to diversify its AI business by expanding into software platforms that complement its leadership in AI chips and accelerated computing.

For investors, the announcements demonstrate Nvidia's continued investment in high-growth markets such as robotics, industrial automation and AI-powered drug discovery, while further strengthening its ecosystem of enterprise AI products.

Conclusion

Nvidia continues to broaden its AI portfolio beyond hardware with new platforms targeting robotics safety and life sciences research. The latest launches underscore the company's strategy of building an integrated AI ecosystem that supports enterprise adoption across multiple industries.